miRNA cassettes in viral vectors: problems and solutions.

The discovery of RNA interference (RNAi), an evolutionary conserved gene silencing mechanism that is triggered by double stranded RNA, has led to tremendous efforts to use this technology for basic research and new RNA therapeutics. RNAi can be induced via transfection of synthetic small interfering RNAs (siRNAs), which results in a transient knockdown of the targeted mRNA. For stable gene silencing, short hairpin RNA (shRNA) or microRNA (miRNA) constructs have been developed. In mammals and humans, the natural RNAi pathway is triggered via endogenously expressed miRNAs. The use of modified miRNA expression cassettes to elucidate fundamental biological questions or to develop therapeutic strategies has received much attention. Viral vectors are particularly useful for the delivery of miRNA genes to specific target cells. To date, many viral vectors have been developed, each with distinct characteristics that make one vector more suitable for a certain purpose than others. This review covers the recent progress in miRNA-based gene-silencing approaches that use viral vectors, with a focus on their unique properties, respective limitations and possible solutions. Furthermore, we discuss a related topic that involves the insertion of miRNA-target sequences in viral vector systems to restrict their cellular range of gene expression. This article is part of a Special Issue entitled: MicroRNAs in viral gene regulation.

[1]  Jaap Kool,et al.  High-throughput insertional mutagenesis screens in mice to identify oncogenic networks , 2009, Nature Reviews Cancer.

[2]  G. Jayandharan,et al.  Activation of the NF-κB pathway by adeno-associated virus (AAV) vectors and its implications in immune response and gene therapy , 2011, Proceedings of the National Academy of Sciences.

[3]  J. Karn,et al.  RNA recognition by the human immunodeficiency virus Tat and Rev proteins. , 1993, Trends in biochemical sciences.

[4]  D. Russell,et al.  Adeno-associated virus vector integration junctions , 1997, Journal of virology.

[5]  Christof von Kalle,et al.  The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. , 2009, The Journal of clinical investigation.

[6]  R. Herzog,et al.  Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. , 2009, Blood.

[7]  K. Moelling,et al.  Dicer is involved in protection against influenza A virus infection. , 2007, The Journal of general virology.

[8]  S. Kung,et al.  Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. , 1998, Blood.

[9]  U. Kutay,et al.  Nuclear Export of MicroRNA Precursors , 2004, Science.

[10]  Danish Sayed,et al.  MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. , 2008, Molecular biology of the cell.

[11]  G. Ruvkun,et al.  Negative regulatory sequences in the lin-14 3'-untranslated region are necessary to generate a temporal switch during Caenorhabditis elegans development. , 1991, Genes & development.

[12]  Michael Karin,et al.  Intracellular pattern recognition receptors in the host response , 2006, Nature.

[13]  Wei Ge,et al.  Synthetic shRNAs as potent RNAi triggers , 2005, Nature Biotechnology.

[14]  D. Bartel,et al.  MicroRNA-Directed Cleavage of HOXB8 mRNA , 2004, Science.

[15]  E. Furth,et al.  Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  T. Hino,et al.  Escape from the interferon response associated with RNA interference using vectors that encode long modified hairpin-RNA. , 2005, Molecular bioSystems.

[17]  Sanghyuk Lee,et al.  MicroRNA genes are transcribed by RNA polymerase II , 2004, The EMBO journal.

[18]  Takeshi Suzuki,et al.  RTCGD: retroviral tagged cancer gene database , 2004, Nucleic Acids Res..

[19]  J. Lieberman,et al.  Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV. , 2005, Blood.

[20]  J. Ellis,et al.  Retrovirus silencing and vector design: relevance to normal and cancer stem cells? , 2005, Current gene therapy.

[21]  Gianluigi Zanetti,et al.  Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. , 2011, Blood.

[22]  Christof von Kalle,et al.  Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. , 2009, Nature medicine.

[23]  S. Kochanek,et al.  Persistence in muscle of an adenoviral vector that lacks all viral genes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Inder M Verma,et al.  Sustained suppression of Bcr-Abl-driven lymphoid leukemia by microRNA mimics , 2007, Proceedings of the National Academy of Sciences.

[25]  J. Ellis.  Silencing and variegation of gammaretrovirus and lentivirus vectors. , 2005, Human gene therapy.

[26]  E. Lai,et al.  Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesis , 2010, Proceedings of the National Academy of Sciences.

[27]  John J. Rossi,et al.  Strategies for silencing human disease using RNA interference , 2007, Nature Reviews Genetics.

[28]  A. Annoni,et al.  A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. , 2007, Blood.

[29]  B. Berkhout,et al.  Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron , 2008, Nucleic acids research.

[30]  J. He,et al.  Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1 , 2005, Gene Therapy.

[31]  T. Tuschl,et al.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.

[32]  M. Kay,et al.  From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. , 2003, Current gene therapy.

[33]  Theresa A. Storm,et al.  Large-Scale Molecular Characterization of Adeno-Associated Virus Vector Integration in Mouse Liver , 2005, Journal of Virology.

[34]  Robert Langer,et al.  Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.

[35]  J. Bergelson,et al.  Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5 , 1997, Science.

[36]  L. Lim,et al.  MicroRNA targeting specificity in mammals: determinants beyond seed pairing. , 2007, Molecular cell.

[37]  B. Berkhout,et al.  Regulation of HIV expression: mechanisms of action of Tat and Rev. , 1991, AIDS.

[38]  A. Beaudet,et al.  High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity. , 1998, Human gene therapy.

[39]  Theresa A. Storm,et al.  Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. , 2010, The Journal of clinical investigation.

[40]  F. Holstege,et al.  Specific inhibition of gene expression using a stably integrated, inducible small‐interfering‐RNA vector , 2003, EMBO reports.

[41]  C. Croce,et al.  MicroRNA-133 controls cardiac hypertrophy , 2007, Nature Medicine.

[42]  Justine R. Smith,et al.  Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 , 2008, Nature.

[43]  Yang Du,et al.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1 , 2006, Nature Medicine.

[44]  B. Berkhout,et al.  The Ebola Virus VP35 Protein Is a Suppressor of RNA Silencing , 2007, PLoS pathogens.

[45]  T. Hope,et al.  The ins and outs of HIV Rev. , 1999, Archives of biochemistry and biophysics.

[46]  T. Tuschl,et al.  Small interfering RNAs: a revolutionary tool for the analysis of gene function and gene therapy. , 2002, Molecular interventions.

[47]  M. Manoharan,et al.  RNAi therapeutics: a potential new class of pharmaceutical drugs , 2006, Nature chemical biology.

[48]  A. Jetzt,et al.  Human Immunodeficiency Virus Type 1 Recombination: Rate, Fidelity, and Putative Hot Spots , 2002, Journal of Virology.

[49]  Sridhar Hannenhalli,et al.  Genome-wide analysis of retroviral DNA integration , 2005, Nature Reviews Microbiology.

[50]  A. Fire,et al.  Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[51]  B. Berkhout,et al.  Combinatorial RNAi Against HIV-1 Using Extended Short Hairpin RNAs. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[52]  B. Berkhout,et al.  Combinatorial RNAi strategies against HIV-1 and other escape-prone viruses , 2008 .

[53]  M. Kohara,et al.  Intracellular-diced dsRNA has enhanced efficacy for silencing HCV RNA and overcomes variation in the viral genotype , 2006, Gene Therapy.

[54]  F. Bushman,et al.  Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site Preferences , 2004, PLoS biology.

[55]  Brian L. Gilmore,et al.  Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi , 2008, Proceedings of the National Academy of Sciences.

[56]  E Marshall,et al.  Gene Therapy Death Prompts Review of Adenovirus Vector , 1999, Science.

[57]  H. Klenk,et al.  The Ebola Virus VP35 Protein Inhibits Activation of Interferon Regulatory Factor 3 , 2003, Journal of Virology.

[58]  B. Reinhart,et al.  Small RNAs Correspond to Centromere Heterochromatic Repeats , 2002, Science.

[59]  Patrick J. Paddison,et al.  Second-generation shRNA libraries covering the mouse and human genomes , 2005, Nature Genetics.

[60]  S. Le,et al.  Evidence that HIV-1 encodes an siRNA and a suppressor of RNA silencing. , 2005, Immunity.

[61]  Luigi Naldini,et al.  Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state , 2007, Nature Biotechnology.

[62]  M. Kohara,et al.  Effective Suppression of Human Immunodeficiency Virus Type 1 through a Combination of Short- or Long-Hairpin RNAs Targeting Essential Sequences for Retroviral Integration , 2006, Journal of Virology.

[63]  B. Davidson,et al.  RNA polymerase III transcribes human microRNAs , 2006, Nature Structural &Molecular Biology.

[64]  N. Lau.  Small RNAs in the animal gonad: guarding genomes and guiding development. , 2010, The international journal of biochemistry & cell biology.

[65]  E. Galanis,et al.  Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress , 2007, Nature Clinical Practice Oncology.

[66]  Anitha Rao,et al.  RNA-Based Gene Therapy for HIV with Lentiviral Vector–Modified CD34+ Cells in Patients Undergoing Transplantation for AIDS-Related Lymphoma , 2010, Science Translational Medicine.

[67]  N. Bessis,et al.  Immune responses to gene therapy vectors: influence on vector function and effector mechanisms , 2004, Gene therapy.

[68]  A. Kingsman,et al.  A Rev-Independent Human Immunodeficiency Virus Type 1 (HIV-1)-Based Vector That Exploits a Codon-Optimized HIV-1gag-pol Gene , 2000, Journal of virology.

[69]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[70]  Jennifer Taylor,et al.  Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155 , 2006, Nucleic acids research.

[71]  S. Kauppinen,et al.  LNA-mediated microRNA silencing in non-human primates , 2008, Nature.

[72]  B. Berkhout.  Hepatitis C virus therapy: blocking the little microRNA helper of the virus. , 2010, Journal of the Formosan Medical Association = Taiwan yi zhi.

[73]  T. Flotte,et al.  Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors , 2001, Gene Therapy.

[74]  J. Rossi,et al.  Expression of long anti-HIV-1 hairpin RNAs for the generation of multiple siRNAs: advantages and limitations. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[75]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[76]  Gregory J. Hannon,et al.  MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies , 2005, Nature Cell Biology.

[77]  M. Mann,et al.  miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs. , 2002, Genes & development.

[78]  M. Kay,et al.  Combinatorial RNAi: A Winning Strategy for the Race Against Evolving Targets? , 2007, Molecular Therapy.

[79]  A. Amalfitano,et al.  Next-generation adenoviral vectors: new and improved , 1999, Gene Therapy.

[80]  Kenneth Chang,et al.  Lessons from Nature: microRNA-based shRNA libraries , 2006, Nature Methods.

[81]  John B. Shoven,et al.  I , Edinburgh Medical and Surgical Journal.

[82]  R. Zinkernagel.  On natural and artificial vaccinations. , 2003, Annual review of immunology.

[83]  N. Van Rooijen,et al.  Use of Tissue-Specific MicroRNA to Control Pathology of Wild-Type Adenovirus without Attenuation of Its Ability to Kill Cancer Cells , 2009, PLoS pathogens.

[84]  T. Mak,et al.  HIV-1 Tat directly interacts with the interferon-induced, double-stranded RNA-dependent kinase, PKR. , 1995, Virology.

[85]  P. Kantoff,et al.  Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[86]  V. Ambros.  The functions of animal microRNAs , 2004, Nature.

[87]  J. Murray,et al.  Cassette deletion in multiple shRNA lentiviral vectors for HIV-1 and its impact on treatment success , 2009, Virology Journal.

[88]  Robert H. Silverman,et al.  Activation of the interferon system by short-interfering RNAs , 2003, Nature Cell Biology.

[89]  P. Waterhouse,et al.  Virus resistance and gene silencing in plants can be induced by simultaneous expression of sense and antisense RNA. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[90]  Donald W. Pfaff,et al.  Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain , 1994, Nature Genetics.

[91]  D. Felsher,et al.  Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[92]  Frederic D Bushman,et al.  Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[93]  R. Bernards,et al.  A System for Stable Expression of Short Interfering RNAs in Mammalian Cells , 2002, Science.

[94]  C. Rogler,et al.  Multi-miRNA hairpin method that improves gene knockdown efficiency and provides linked multi-gene knockdown. , 2006, BioTechniques.

[95]  Manfred Schmidt,et al.  Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy , 2009, Science.

[96]  D. Palmer,et al.  Improved system for helper-dependent adenoviral vector production. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[97]  J. Wilson,et al.  Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[98]  Eric J Wagner,et al.  Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. , 2002, Molecular cell.

[99]  G. Dickson,et al.  Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1 , 2009, Proceedings of the National Academy of Sciences.

[100]  C. Burge,et al.  Prediction of Mammalian MicroRNA Targets , 2003, Cell.

[101]  M. Vignuzzi,et al.  Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines. , 2008, Cell host & microbe.

[102]  K. Morris,et al.  The Efficacy of Generating Three Independent Anti-HIV-1 siRNAs from a Single U6 RNA Pol III-Expressed Long Hairpin RNA , 2008, PloS one.

[103]  G. Hannon,et al.  The Piwi-piRNA Pathway Provides an Adaptive Defense in the Transposon Arms Race , 2007, Science.

[104]  B. Ramratnam,et al.  Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. , 2004, Nucleic acids research.

[105]  D. Bartel,et al.  Intronic microRNA precursors that bypass Drosha processing , 2007, Nature.

[106]  R. Iggo,et al.  Induction of an interferon response by RNAi vectors in mammalian cells , 2003, Nature Genetics.

[107]  Florian Caiment,et al.  RNAi-Mediated Allelic trans-Interaction at the Imprinted Rtl1/Peg11 Locus , 2005, Current Biology.

[108]  Theresa A. Storm,et al.  DNA palindromes with a modest arm length of greater, similar 20 base pairs are a significant target for recombinant adeno-associated virus vector integration in the liver, muscles, and heart in mice. , 2007, Journal of virology.

[109]  A. Saïb,et al.  A Cellular MicroRNA Mediates Antiviral Defense in Human Cells , 2005, Science.

[110]  W. Gerlach,et al.  Long‐term survival and concomitant gene expression of ribozyme‐transduced CD4+ T‐lymphocytes in HIV‐infected patients , 2005, The journal of gene medicine.

[111]  J. Castle,et al.  Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs , 2005, Nature.

[112]  D. Bellinger,et al.  Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency. , 2009, ILAR journal.

[113]  Leemor Joshua-Tor,et al.  Slicer and the argonautes. , 2007, Nature chemical biology.

[114]  D. Trono,et al.  A Third-Generation Lentivirus Vector with a Conditional Packaging System , 1998, Journal of Virology.

[115]  D. Levy,et al.  Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. , 1998, Virology.

[116]  Demin Zhou,et al.  A method for detecting and preventing negative RNA interference in preparation of lentiviral vectors for siRNA delivery. , 2009, RNA.

[117]  Mark Graham,et al.  miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. , 2006, Cell metabolism.

[118]  D. Muruve,et al.  The innate immune response to adenovirus vectors. , 2004, Human gene therapy.

[119]  Ben Berkhout,et al.  Silencing of HIV-1 with RNA interference: a multiple shRNA approach. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[120]  I. Plavec,et al.  Construction and Molecular Analysis of Gene Transfer Systems Derived from Bovine Immunodeficiency Virus , 2001, Journal of Virology.

[121]  A. Pasquinelli,et al.  A Cellular Function for the RNA-Interference Enzyme Dicer in the Maturation of the let-7 Small Temporal RNA , 2001, Science.

[122]  Margaret S. Ebert,et al.  MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells , 2007, Nature Methods.

[123]  Theresa A. Storm,et al.  DNA Palindromes with a Modest Arm Length of ≳20 Base Pairs Are a Significant Target for Recombinant Adeno-Associated Virus Vector Integration in the Liver, Muscles, and Heart in Mice , 2007, Journal of Virology.

[124]  T. Flotte,et al.  Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[125]  Jie Chen,et al.  Lentiviral‐mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma , 2008, Hepatology.

[126]  B. Berkhout,et al.  RNA interference against viruses: strike and counterstrike , 2007, Nature Biotechnology.

[127]  James M. Wilson,et al.  Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 Gag vaccines. , 2008, Human gene therapy.

[128]  B. Berkhout,et al.  Increased virus replication in mammalian cells by blocking intracellular innate defense responses , 2008, Gene Therapy.

[129]  J. Prieto,et al.  Treatment of Chronic Viral Hepatitis in Woodchucks by Prolonged Intrahepatic Expression of Interleukin-12 , 2008, Journal of Virology.

[130]  S. Russell,et al.  Engineering microRNA responsiveness to decrease virus pathogenicity , 2008, Nature Medicine.

[131]  A. Ganser,et al.  Lentivirus-mediated antagomir expression for specific inhibition of miRNA function , 2007, Nucleic acids research.

[132]  M. Sadelain,et al.  Harnessing endogenous miR-181a to segregate transgenic antigen receptor expression in developing versus post-thymic T cells in murine hematopoietic chimeras. , 2008, The Journal of clinical investigation.

[133]  J. Chamberlain,et al.  Recombinant adeno-associated virus transduction and integration. , 2008, Molecular Therapy.

[134]  N. Rajewsky,et al.  Silencing of microRNAs in vivo with ‘antagomirs’ , 2005, Nature.

[135]  H. Jäck,et al.  A facile method to increase titers of miRNA‐encoding retroviruses by inhibition of the RNaseIII enzyme Drosha , 2011, European journal of immunology.

[136]  M. Simon,et al.  A versatile approach to multiple gene RNA interference using microRNA-based short hairpin RNAs , 2007, BMC Molecular Biology.

[137]  Shou-Wei Ding,et al.  Interferon antagonist proteins of influenza and vaccinia viruses are suppressors of RNA silencing. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[138]  Anne Gatignol,et al.  Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC , 2007, Nucleic acids research.

[139]  J. Douglas,et al.  Adenoviral vectors for gene therapy , 2007, Molecular biotechnology.

[140]  J. Kjems,et al.  Rev protein and its cellular partners. , 2000, Advances in pharmacology.

[141]  O. Aparicio,et al.  Adenovirus Virus-Associated RNA Is Processed to Functional Interfering RNAs Involved in Virus Production , 2006, Journal of Virology.

[142]  M. Amarzguioui,et al.  Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor. , 2002, Nucleic acids research.

[143]  G. Nemerow,et al.  Integrins α v β 3 and α v β 5 promote adenovirus internalization but not virus attachment , 1993, Cell.

[144]  M. Amarzguioui,et al.  Engineering and optimization of the mir-106b-cluster for ectopic expression of multiplexed anti-HIV RNAs , 2008, Gene Therapy.

[145]  J. Steel,et al.  MicroRNA-mediated species-specific attenuation of influenza A virus , 2009, Nature Biotechnology.

[146]  Daniel G. Miller,et al.  Adeno-associated virus vectors integrate at chromosome breakage sites , 2004, Nature Genetics.

[147]  Egbert Oosterwijk,et al.  Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. , 2011, Blood.

[148]  S. Weger,et al.  Viral vectors for gene transfer: current status of gene therapeutics. , 2010, Handbook of experimental pharmacology.

[149]  F. Graham,et al.  Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A. , 2004, Blood.

[150]  Christine Kinnon,et al.  Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. , 2007, The Journal of clinical investigation.

[151]  T. Tuschl,et al.  RNA interference is mediated by 21- and 22-nucleotide RNAs. , 2001, Genes & development.

[152]  K. Gunsalus,et al.  Combinatorial microRNA target predictions , 2005, Nature Genetics.

[153]  E. Poeschla,et al.  Identification of a Human Immunodeficiency Virus Type 2 (HIV-2) Encapsidation Determinant and Transduction of Nondividing Human Cells by HIV-2-Based Lentivirus Vectors , 1998, Journal of Virology.

[154]  B. Berkhout,et al.  Titers of lentiviral vectors encoding shRNAs and miRNAs are reduced by different mechanisms that require distinct repair strategies. , 2010, RNA.

[155]  F. Graham,et al.  Packaging capacity and stability of human adenovirus type 5 vectors , 1993, Journal of virology.

[156]  V. Volchkov,et al.  The Ebola virus VP35 protein functions as a type I IFN antagonist. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[157]  B. Williams,et al.  HIV-I TAT inhibits PKR activity by both RNA-dependent and RNA-independent mechanisms. , 2000, Archives of biochemistry and biophysics.

[158]  Stefan L Ameres,et al.  MicroRNA-regulated, Systemically Delivered rAAV9: A Step Closer to CNS-restricted Transgene Expression , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[159]  Anne Gatignol,et al.  TRBP, a regulator of cellular PKR and HIV‐1 virus expression, interacts with Dicer and functions in RNA silencing , 2005, EMBO reports.

[160]  S. Cole,et al.  Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. , 2004, Human gene therapy.

[161]  G. Meister,et al.  The Argonaute protein family , 2008, Genome Biology.

[162]  Chunyan Liu,et al.  Nerve injection of viral vectors efficiently transfers transgenes into motor neurons and delivers RNAi therapy against ALS. , 2009, Antioxidants & redox signaling.

[163]  O. Aparicio,et al.  Effect of Adenovirus-Mediated RNA Interference on Endogenous MicroRNAs in a Mouse Model of Multidrug Resistance Protein 2 Gene Silencing , 2006, Journal of Virology.

[164]  D. Grimm.  Small silencing RNAs: state-of-the-art. , 2009, Advanced drug delivery reviews.

[165]  Shawn M. Burgess,et al.  Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration , 2003, Science.

[166]  Pascal Barbry,et al.  Suppression of MicroRNA-Silencing Pathway by HIV-1 During Virus Replication , 2007, Science.

[167]  P. Aebischer,et al.  Viral-based modelling and correction of neurodegenerative diseases by RNA interference , 2006, Gene Therapy.

[168]  John J Rossi,et al.  Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[169]  R. Akkina,et al.  CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection , 2005, Retrovirology.

[170]  Y. Sung,et al.  Comparison of various expression plasmids for the induction of immune response by DNA immunization. , 1997, Molecules and cells.

[171]  H. Lipkin.  Where is the ?c? , 1978 .

[172]  R. Shiekhattar,et al.  TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing , 2005, Nature.

[173]  Marco Vignuzzi,et al.  Engineering attenuated virus vaccines by controlling replication fidelity , 2008, Nature Medicine.

[174]  J. Sommer,et al.  Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. , 2006, Blood.

[175]  R. Andino,et al.  Generation of a Conditionally Replicating Adenovirus Based on Targeted Destruction of E1A mRNA by a Cell Type-Specific MicroRNA , 2008, Journal of Virology.

[176]  Jim Hu,et al.  Adenoviral vectors for gene replacement therapy. , 2004, Viral immunology.

[177]  G. Ciliberto,et al.  An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[178]  V. Kim,et al.  Biogenesis of small RNAs in animals , 2009, Nature Reviews Molecular Cell Biology.

[179]  P. Arbuthnot,et al.  Therapeutic potential of adenoviral vectors for delivery of expressed RNAi activators , 2010, Expert opinion on drug delivery.

[180]  B. Cullen,et al.  Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. , 2003, Genes & development.

[181]  B. Li,et al.  Expression profiling reveals off-target gene regulation by RNAi , 2003, Nature Biotechnology.

[182]  Samantha Barichievy,et al.  Specific inhibition of HBV replication in vitro and in vivo with expressed long hairpin RNA. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[183]  J. M. Thomson,et al.  Argonaute2 Is the Catalytic Engine of Mammalian RNAi , 2004, Science.

[184]  Prashant Patel,et al.  Antivector and tumor immune responses following adenovirus-directed enzyme prodrug therapy for the treatment of prostate cancer. , 2009, Human gene therapy.

[185]  Hiromu Suzuki,et al.  A Single Recombinant Adenovirus Expressing p53 and p21-targeting Artificial microRNAs Efficiently Induces Apoptosis in Human Cancer Cells , 2009, Clinical Cancer Research.

[186]  Devan V Mehrotra,et al.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial , 2008, The Lancet.

[187]  John R. Mascola,et al.  Gene transfer in humans using a conditionally replicating lentiviral vector , 2006, Proceedings of the National Academy of Sciences.

[188]  T. McCown.  Adeno-Associated Virus (AAV) Vectors in the CNS. , 2005, Current gene therapy.

[189]  S. Ponnazhagan,et al.  Evaluation of recombinant adeno-associated virus as a gene transfer vector for the retina. , 1997, Current eye research.

[190]  Haibin Xia,et al.  siRNA-mediated gene silencing in vitro and in vivo , 2002, Nature Biotechnology.

[191]  M. Kumar,et al.  Systematic determination of the packaging limit of lentiviral vectors. , 2001, Human gene therapy.

[192]  B. Berkhout,et al.  Lentiviral vectors that carry anti‐HIV shRNAs: problems and solutions , 2007, The journal of gene medicine.

[193]  E. Poeschla,et al.  Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors , 1998, Nature Medicine.

[194]  V. Ambros,et al.  The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 , 1993, Cell.

[195]  L. Naldini,et al.  Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[196]  P. Andersen.  Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene , 2006, Current neurology and neuroscience reports.

[197]  Martin J. Simard,et al.  Argonaute proteins: key players in RNA silencing , 2008, Nature Reviews Molecular Cell Biology.

[198]  A. Ely,et al.  Efficient silencing of gene expression with modular trimeric Pol II expression cassettes comprising microRNA shuttles , 2009, Nucleic acids research.

[199]  Alessandra Biffi,et al.  Identification of Hematopoietic Stem Cell–Specific miRNAs Enables Gene Therapy of Globoid Cell Leukodystrophy , 2010, Science Translational Medicine.

[200]  G. Hannon,et al.  A dicer-independent miRNA biogenesis pathway that requires Ago catalysis , 2010, Nature.

[201]  B. Berkhout,et al.  Design of extended short hairpin RNAs for HIV-1 inhibition , 2007, Nucleic Acids Research.

[202]  B. Berkhout,et al.  In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[203]  Miss A.O. Penney.  (b) , 1974, The New Yale Book of Quotations.

[204]  M. Betts,et al.  Adenovirus-Specific Immunity Following Immunization with an Ad5 HIV-1 Vaccine Candidate in Humans , 2009, Nature Medicine.

[205]  K. Taira,et al.  Short hairpin type of dsRNAs that are controlled by tRNA(Val) promoter significantly induce RNAi-mediated gene silencing in the cytoplasm of human cells. , 2003, Nucleic acids research.

[206]  Theresa A. Storm,et al.  AAV serotype 2 vectors preferentially integrate into active genes in mice , 2003, Nature Genetics.

[207]  J. Pagès,et al.  Toolbox for retrovectorologists , 2004, The journal of gene medicine.

[208]  T. Mayumi,et al.  Optimization of transcriptional regulatory elements for constructing plasmid vectors. , 2001, Gene.

[209]  K. Yagi,et al.  miR-122a-Regulated Expression of a Suicide Gene Prevents Hepatotoxicity Without Altering Antitumor Effects in Suicide Gene Therapy. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[210]  E. Kremmer,et al.  Prevention of interferon-stimulated gene expression using microRNA-designed hairpins , 2009, Gene Therapy.

[211]  A. Annoni,et al.  Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. , 2004, Blood.

[212]  Jing Qu,et al.  Artificial MicroRNA-Mediated Virus Resistance in Plants , 2007, Journal of Virology.

[213]  David W. Taylor,et al.  A Novel miRNA Processing Pathway Independent of Dicer Requires Argonaute2 Catalytic Activity , 2010, Science.

[214]  Paul Shinn,et al.  Retroviral DNA Integration: Viral and Cellular Determinants of Target-Site Selection , 2006, PLoS pathogens.

[215]  G. Hannon,et al.  Crystal Structure of Argonaute and Its Implications for RISC Slicer Activity , 2004, Science.

[216]  M. Manns,et al.  p53-dependent antiviral RNA-interference facilitates tumor-selective viral replication , 2009, Nucleic acids research.

[217]  C. Baum.  Insertional mutagenesis in gene therapy and stem cell biology , 2007, Current opinion in hematology.

[218]  D. Bartel,et al.  MicroRNAs Modulate Hematopoietic Lineage Differentiation , 2004, Science.

[219]  A. Schambach,et al.  Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors , 2006, Gene Therapy.

[220]  E. Bucher,et al.  The influenza A virus NS1 protein binds small interfering RNAs and suppresses RNA silencing in plants. , 2004, The Journal of general virology.

[221]  Daniel G. Miller,et al.  AAV Vector Integration Sites in Mouse Hepatocellular Carcinoma , 2007, Science.

[222]  R R Ali,et al.  AAV-mediated knockdown of Peripherin-2 in vivo using miRNA-based hairpins , 2010, Gene Therapy.

[223]  W. An,et al.  Frequency of direct repeat deletion in a human immunodeficiency virus type 1 vector during reverse transcription in human cells. , 2001, Virology.

[224]  R. Russell,et al.  Principles of MicroRNA–Target Recognition , 2005, PLoS biology.

[225]  Luigi Naldini,et al.  Stable knockdown of microRNA in vivo by lentiviral vectors , 2009, Nature Methods.

[226]  H. Soifer,et al.  A potential role for RNA interference in controlling the activity of the human LINE-1 retrotransposon , 2005, Nucleic acids research.

[227]  Clelia Di Serio,et al.  Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration , 2006, Nature Biotechnology.

[228]  A. Jetzt,et al.  High Rate of Recombination throughout the Human Immunodeficiency Virus Type 1 Genome , 2000, Journal of Virology.

[229]  S. Kauppinen,et al.  Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection , 2010, Science.

[230]  P. Mangeot,et al.  Development of Minimal Lentivirus Vectors Derived from Simian Immunodeficiency Virus (SIVmac251) and Their Use for Gene Transfer into Human Dendritic Cells , 2000, Journal of Virology.

[231]  Donald K Carter,et al.  HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis , 2008, The Lancet.

[232]  Theresa A. Storm,et al.  Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways , 2006, Nature.

[233]  B. Berkhout,et al.  Inhibition of human immunodeficiency virus type 1 by RNA interference using long-hairpin RNA , 2006, Gene Therapy.

[234]  B. Cullen,et al.  MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[235]  J. Bell,et al.  Recent progress in the battle between oncolytic viruses and tumours , 2005, Nature Reviews Cancer.

[236]  V. Kim,et al.  The Drosha-DGCR8 complex in primary microRNA processing. , 2004, Genes & development.

[237]  G. Hannon,et al.  Inducible, reversible, and stable RNA interference in mammalian cells , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[238]  Sheena M Saayman,et al.  Deriving four functional anti-HIV siRNAs from a single Pol III-generated transcript comprising two adjacent long hairpin RNA precursors , 2010, Nucleic acids research.

[239]  A. Thrasher,et al.  Gene therapy for severe combined immunodeficiencies , 2005, Expert opinion on biological therapy.

[240]  L. Steel,et al.  RNA polymerase III can drive polycistronic expression of functional interfering RNAs designed to resemble microRNAs , 2009, Nucleic acids research.

[241]  A. Fassati,et al.  Nuclear Import of Viral DNA Genomes , 2003, Traffic.

[242]  Hojun Li,et al.  Assessing the potential for AAV vector genotoxicity in a murine model. , 2011, Blood.

[243]  F. Graham,et al.  A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging , 1997, Journal of virology.

[244]  M. Sadelain,et al.  The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the ltr, and the promise of lineage-restricted vectors. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[245]  V. Ambros,et al.  MicroRNAs and Other Tiny Endogenous RNAs in C. elegans , 2003, Current Biology.

[246]  P. Rennie,et al.  MicroRNA Regulation of Oncolytic Herpes Simplex Virus-1 for Selective Killing of Prostate Cancer Cells , 2009, Clinical Cancer Research.

[247]  H. Atkins,et al.  A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[248]  M. Kay,et al.  Isolation of Recombinant Adeno-Associated Virus Vector-Cellular DNA Junctions from Mouse Liver , 1999, Journal of Virology.

[249]  E. Kruithof,et al.  Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors , 2004, BMC Molecular Biology.

[250]  K. Morris,et al.  The inhibitory efficacy of RNA POL III-expressed long hairpin RNAs targeted to untranslated regions of the HIV-1 5' long terminal repeat. , 2007, Oligonucleotides.

[251]  Ji-Joon Song,et al.  Purified Argonaute2 and an siRNA form recombinant human RISC , 2005, Nature Structural &Molecular Biology.

[252]  R. Sutton,et al.  Titers of HIV-based vectors encoding shRNAs are reduced by a dicer-dependent mechanism. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[253]  I. Martins,et al.  Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[254]  L. Naldini,et al.  Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer , 2006, Nature Medicine.

[255]  Daniel G. Miller,et al.  15. Large-Scale Analysis of Adeno-Associated Virus Vector Integration Sites in Normal Human Cells , 2005 .

[256]  Eugene Berezikov,et al.  Mammalian mirtron genes. , 2007, Molecular cell.

[257]  Stefan Fruehauf,et al.  Lentiviral vector integration sites in human NOD/SCID repopulating cells , 2006, The journal of gene medicine.